Literature DB >> 14612430

LPS resistance in monocytic cells caused by reverse signaling through transmembrane TNF (mTNF) is mediated by the MAPK/ERK pathway.

Silvia Kirchner1, Simone Boldt, Walter Kolch, Silvia Haffner, Seran Kazak, Petra Janosch, Ernst Holler, Reinhard Andreesen, Günther Eissner.   

Abstract

The transmembrane form of tumor necrosis factor (mTNF), expressed on activated monocytes (MO) and macrophages (MPhi), is able to induce apoptosis in human endothelial cells (EC). Apoptosis is mediated by two distinct mechanisms: direct cell contact and a yet-unidentified soluble protein, death factor X. In addition, mTNF acts as a receptor that transduces a "reverse signal" into MO/MPhi when bound to the TNF receptor on EC. Reverse signaling by mTNF confers resistance to bacterial lipopolysaccharide (LPS). Stimulation of reverse signaling by mTNF blocks the ability of MO/MPhi to produce death factor X and proinflammatory cytokines. We have investigated which signaling pathways are used by mTNF acting as receptor. Reverse signaling triggers two independent pathways that can be distinguished by protein kinase C (PKC) inhibitors. The suppression of LPS-induced death factor X is dependent on PKC, whereas the suppression of LPS-mediated cytokine release is not. LPS and reverse signaling stimulate the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway. It is interesting that the activation of reverse signaling by mTNF renders MO/MPhi refractory to a subsequent activation of the MAPK/ERK pathway by LPS. Thus, reverse signaling achieves LPS resistance in monocytic cells through interference with key signal-transduction pathways.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14612430     DOI: 10.1189/jlb.0703343

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  20 in total

Review 1.  The evolving experience with therapeutic TNF inhibition in sepsis: considering the potential influence of risk of death.

Authors:  Ping Qiu; Xizhong Cui; Amisha Barochia; Yan Li; Charles Natanson; Peter Q Eichacker
Journal:  Expert Opin Investig Drugs       Date:  2011-10-01       Impact factor: 6.206

2.  Chebulagic acid inhibits the LPS-induced expression of TNF-α and IL-1β in endothelial cells by suppressing MAPK activation.

Authors:  Yueying Liu; Luer Bao; Liying Xuan; Baohua Song; Lin Lin; Hao Han
Journal:  Exp Ther Med       Date:  2015-04-23       Impact factor: 2.447

3.  Reverse signalling of membrane-integrated tumour necrosis factor differentially regulates alloresponses of CD4+ and CD8+ T cells against human microvascular endothelial cells.

Authors:  Nalini K Vudattu; Ernst Holler; Patricia Ewing; Ute Schulz; Silvia Haffner; Verena Burger; Silvia Kirchner; Reinhard Andreesen; Günther Eissner
Journal:  Immunology       Date:  2005-08       Impact factor: 7.397

4.  Differential effects of total and partial neutralization of tumor necrosis factor on cell-mediated immunity to Mycobacterium bovis BCG infection.

Authors:  Reto Guler; Maria L Olleros; Dominique Vesin; Roumen Parapanov; Irene Garcia
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

5.  Tumor necrosis factor (TNF) protects resistant C57BL/6 mice against herpes simplex virus-induced encephalitis independently of signaling via TNF receptor 1 or 2.

Authors:  Patric Lundberg; Paula V Welander; Carl K Edwards; Nico van Rooijen; Edouard Cantin
Journal:  J Virol       Date:  2006-11-15       Impact factor: 5.103

6.  Differential requirements for soluble and transmembrane tumor necrosis factor in the immunological control of primary and secondary Listeria monocytogenes infection.

Authors:  Korana Musicki; Helen Briscoe; Stephen Tran; Warwick J Britton; Bernadette M Saunders
Journal:  Infect Immun       Date:  2006-06       Impact factor: 3.441

Review 7.  Neurological adverse events associated with anti-tumor necrosis factor α treatment.

Authors:  Antonio G Tristano
Journal:  J Neurol       Date:  2010-05-22       Impact factor: 4.849

8.  IL-10 Induced by mTNF Crosslinking-Mediated Reverse Signaling in a Whole Blood Assay Is Predictive of Response to TNFi Therapy in Rheumatoid Arthritis.

Authors:  Marco Krasselt; Natalya Gruz; Matthias Pierer; Christoph Baerwald; Ulf Wagner
Journal:  J Pers Med       Date:  2022-06-19

9.  Poxvirus-encoded TNF receptor homolog dampens inflammation and protects from uncontrolled lung pathology during respiratory infection.

Authors:  Zahrah Al Rumaih; Ma Junaliah Tuazon Kels; Esther Ng; Pratikshya Pandey; Sergio M Pontejo; Alí Alejo; Antonio Alcamí; Geeta Chaudhri; Gunasegaran Karupiah
Journal:  Proc Natl Acad Sci U S A       Date:  2020-10-12       Impact factor: 11.205

Review 10.  TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease.

Authors:  Melissa K McCoy; Malú G Tansey
Journal:  J Neuroinflammation       Date:  2008-10-17       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.